PT2235017E - Derivados de espirolidona como agentes contra o cancro - Google Patents
Derivados de espirolidona como agentes contra o cancro Download PDFInfo
- Publication number
- PT2235017E PT2235017E PT08863724T PT08863724T PT2235017E PT 2235017 E PT2235017 E PT 2235017E PT 08863724 T PT08863724 T PT 08863724T PT 08863724 T PT08863724 T PT 08863724T PT 2235017 E PT2235017 E PT 2235017E
- Authority
- PT
- Portugal
- Prior art keywords
- anticancer agents
- spiroindolinone derivatives
- spiroindolinone
- derivatives
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1488807P | 2007-12-19 | 2007-12-19 | |
| US10738108P | 2008-10-22 | 2008-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2235017E true PT2235017E (pt) | 2011-10-13 |
Family
ID=40351961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08863724T PT2235017E (pt) | 2007-12-19 | 2008-12-09 | Derivados de espirolidona como agentes contra o cancro |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7776875B2 (pt) |
| EP (1) | EP2235017B1 (pt) |
| JP (1) | JP2011506524A (pt) |
| KR (1) | KR20100076075A (pt) |
| CN (1) | CN101903388A (pt) |
| AT (1) | ATE524470T1 (pt) |
| AU (1) | AU2008340473A1 (pt) |
| BR (1) | BRPI0820699A2 (pt) |
| CA (1) | CA2708312A1 (pt) |
| DK (1) | DK2235017T3 (pt) |
| ES (1) | ES2372903T3 (pt) |
| IL (1) | IL205506A0 (pt) |
| MX (1) | MX2010006332A (pt) |
| PL (1) | PL2235017T3 (pt) |
| PT (1) | PT2235017E (pt) |
| WO (1) | WO2009080488A1 (pt) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100190814A1 (en) * | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
| US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8076482B2 (en) * | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| CA2780547C (en) | 2009-11-12 | 2015-02-03 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| EA201390682A1 (ru) | 2010-11-12 | 2014-01-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
| SI2684880T1 (en) * | 2011-03-10 | 2018-08-31 | Daiichi Sankyo Company, Limited | DERIVAT DISPIROPYROLIDINE |
| JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| SI3141542T1 (sl) | 2011-12-28 | 2020-11-30 | Global Blood Therapeutics, Inc. | Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva |
| CN102838610B (zh) * | 2012-08-28 | 2014-09-10 | 吕叶叶 | 双吲哚二氧杂双环辛二酮 |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| JP6266659B2 (ja) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN105246477A (zh) | 2013-03-15 | 2016-01-13 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR101971385B1 (ko) | 2013-03-15 | 2019-04-22 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| WO2014145040A1 (en) * | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| EA028529B1 (ru) | 2014-02-07 | 2017-11-30 | Глобал Блад Терапьютикс, Инк. | Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| ES2968789T3 (es) | 2015-02-20 | 2024-05-14 | Daiichi Sankyo Co Ltd | Procedimiento combinado para el tratamiento del cáncer |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| JP6823587B2 (ja) | 2015-04-13 | 2021-02-03 | 第一三共株式会社 | Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法 |
| EP3359542B1 (en) | 2015-10-09 | 2021-03-17 | Boehringer Ingelheim International GmbH | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| MX2018006832A (es) | 2015-12-04 | 2018-11-09 | Global Blood Therapeutics Inc | Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido. |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| KR20190068544A (ko) | 2016-10-17 | 2019-06-18 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법 |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| JP2022514253A (ja) * | 2018-12-18 | 2022-02-10 | ノバルティス アーゲー | Ｎ－（ピリジン－２－イルスルホニル）シクロプロパンカルボキサミド誘導体及びｃｆｔｒ媒介疾患の処置におけるその使用 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN117069647A (zh) * | 2023-07-27 | 2023-11-17 | 兰州大学 | 一种双官能团螺环催化剂及其合成方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218191T3 (es) * | 1999-07-21 | 2004-11-16 | Astrazeneca Ab | Nuevos compuestos. |
| JP5248866B2 (ja) * | 2005-02-22 | 2013-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｄｍ２の小分子阻害剤およびその使用 |
| EP1911753A1 (en) * | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| US20070213341A1 (en) * | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CA2644758A1 (en) * | 2006-03-13 | 2007-09-20 | F. Hoffmann-La Roche Ag | Spiroindolinone derivatives |
| US7495007B2 (en) * | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7784589B2 (en) * | 2006-07-10 | 2010-08-31 | Inventio Ag | Elevator lift cage load measuring assembly |
| US7638548B2 (en) * | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7834179B2 (en) * | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
-
2008
- 2008-11-18 US US12/273,035 patent/US7776875B2/en not_active Expired - Fee Related
- 2008-12-09 ES ES08863724T patent/ES2372903T3/es active Active
- 2008-12-09 CN CN2008801217831A patent/CN101903388A/zh active Pending
- 2008-12-09 WO PCT/EP2008/067061 patent/WO2009080488A1/en active Application Filing
- 2008-12-09 MX MX2010006332A patent/MX2010006332A/es active IP Right Grant
- 2008-12-09 DK DK08863724.4T patent/DK2235017T3/da active
- 2008-12-09 KR KR1020107013353A patent/KR20100076075A/ko active IP Right Grant
- 2008-12-09 CA CA2708312A patent/CA2708312A1/en not_active Abandoned
- 2008-12-09 AT AT08863724T patent/ATE524470T1/de active
- 2008-12-09 JP JP2010538565A patent/JP2011506524A/ja active Pending
- 2008-12-09 PL PL08863724T patent/PL2235017T3/pl unknown
- 2008-12-09 PT PT08863724T patent/PT2235017E/pt unknown
- 2008-12-09 AU AU2008340473A patent/AU2008340473A1/en not_active Abandoned
- 2008-12-09 EP EP08863724A patent/EP2235017B1/en not_active Not-in-force
- 2008-12-09 BR BRPI0820699A patent/BRPI0820699A2/pt not_active IP Right Cessation
-
2010
- 2010-05-03 IL IL205506A patent/IL205506A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008340473A1 (en) | 2009-07-02 |
| PL2235017T3 (pl) | 2012-02-29 |
| EP2235017B1 (en) | 2011-09-14 |
| JP2011506524A (ja) | 2011-03-03 |
| CN101903388A (zh) | 2010-12-01 |
| WO2009080488A1 (en) | 2009-07-02 |
| US20090163512A1 (en) | 2009-06-25 |
| EP2235017A1 (en) | 2010-10-06 |
| IL205506A0 (en) | 2010-12-30 |
| ATE524470T1 (de) | 2011-09-15 |
| KR20100076075A (ko) | 2010-07-05 |
| ES2372903T3 (es) | 2012-01-27 |
| US7776875B2 (en) | 2010-08-17 |
| MX2010006332A (es) | 2010-07-05 |
| CA2708312A1 (en) | 2009-07-02 |
| DK2235017T3 (da) | 2011-10-24 |
| BRPI0820699A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL205506A0 (en) | Spiroindolinone derivatives as anticancer agents | |
| IL205354A0 (en) | Spiroindolinone derivatives | |
| IL193620A0 (en) | Spiroindolinone derivatives | |
| TW200801000A (en) | Spiroindolinone derivatives | |
| MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
| MX2011008176A (es) | Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. | |
| MX2012009186A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| IN2012DN02487A (pt) | ||
| MX2011007886A (es) | Derivado de espiroindolinona piridina. | |
| TW201129571A (en) | Spiroindolinone pyrrolidines | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| WO2009057079A3 (en) | Novel pyrimidine derivatives | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| MY156319A (en) | Spiroheterocyclic n-oxypiperidines as pesticides | |
| TW200740758A (en) | Benzoquinazoline derivatives | |
| IL197197A0 (en) | Oxindole derivatives as anticancer agents | |
| EP2881384A8 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| WO2007084728A3 (en) | 2-imino-benzimidazoles | |
| IL208025A0 (en) | Spiroindolinone derivatives | |
| EP2581372A4 (en) | CYANOCHINOLINDERIVATE | |
| EP2578587A4 (en) | PYRAZOLE DERIVATIVES | |
| TNSN08369A1 (en) | Benzimidazole derivatives | |
| MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
| MY152557A (en) | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |